GenSci and Osteotech settle bone implant litigation
This article was originally published in Clinica
GenSci Regeneration Sciences, the Toronto, Canada-based company with orthobiologics facilities in Irvine, California, and its Eaton, New Jersey rival, Osteotech, have signed a settlement agreement that brings to an end their long-running dispute over osteogenic bone implants. GenSci, which is currently in Chapter 11 bankruptcy protection, will pay Osteotech $7.5m, $1m of which will be payable after it emerges from Chapter 11, and the remainder in 20 quarterly instalments.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.